Each scientific advance in the fight against multiple sclerosis means further hope for patients and their families.

The recent designation by the FDD of tolebrutinib as a “breakthrough therapy” for multiple sclerosis is a new source of hope for the secondary progressive forms of the disease.

By targeting both innate and adaptive immunity, this treatment opens up new therapeutic possibilities and may well transform patient care in the future.

Read it here